Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07730216

Ultrasonographic Predictors of Adductor Canal Block Effectiveness in Total Knee Arthroplasty

Total knee arthroplasty (TKA) is associated with substantial postoperative pain and opioid requirements, making effective multimodal analgesia essential for early mobilization, functional recovery, and reduction of opioid-related adverse events [1,2]. Adductor canal block (ACB) has become a key component of enhanced recovery after surgery (ERAS) protocols because it provides effective anterior knee analgesia while largely preserving quadriceps muscle strength [2-4]. However, analgesic efficacy after ACB remains variable, and some patients require rescue opioid analgesia despite technically successful block placement [5]. Although ultrasound guidance improves block accuracy, factors such as tissue depth, anatomical variations, saphenous nerve visibility, and injectate spread pattern may influence clinical outcomes [6,7]. Prospective evidence regarding the predictive value of these ultrasound-derived parameters for ACB analgesic failure remains limited. Therefore, this study aims to evaluate whether preoperative ultrasound-derived tissue and target parameters-including skin-to-target depth, subcutaneous fat thickness, muscle thickness, saphenous nerve visibility, and injectate spread pattern-can predict ACB analgesic failure and early postoperative analgesic outcomes following TKA.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age ≥18 years
  • Scheduled for elective primary unilateral total knee arthroplasty under spinal anesthesia
  • American Society of Anesthesiologists (ASA) physical status I-III

Exclusion criteria

  • Daily opioid use or chronic pain syndrome
  • Diabetic or other clinically diagnosed peripheral neuropathy
  • Coagulopathy
  • Infection at the injection site
  • Known allergy or hypersensitivity to local anesthetics
  • Revision total knee arthroplasty
  • Conversion from spinal anesthesia to general anesthesia during surgery
  • General anesthesia as the planned anesthetic technique

Treatment and study plan

Adductor Canal Block (ACB) Only

Procedure

The adductor canal block (ACB) will be performed in the post-anesthesia care unit (PACU) after regression of spinal anesthesia.

Primary outcomes

  1. ACB Failure

    Time frame: 0-24 hours

    ACB analgesic failure will be defined as the requirement for rescue analgesia during the first 24 hours after block administration, with intravenous tramadol (1 mg/kg) administered to patients with an NRS pain score ≥4.

Secondary outcomes

  1. Secondary outcome

    Time frame: 0-24 hour

    • Numeric Rating Scale (NRS) Pain Scores

    NRS pain scores at rest and during a standardized movement (active 90° knee flexion) will be recorded at postoperative 1, 6, 12, and 24 hours.

  2. Tramadol Consumption

    Time frame: 0-24 Hours

    • Total Tramadol Consumption

    Total tramadol consumption (mg) during the first 24 hours following ACB administration will be recorded.

Study contacts

Contact information is provided by the study sponsor or research team.

Ömer Keklicek, Principal Investigator

CONTACT

[email protected]

+905399291702

Sponsors and collaborators

Lead sponsor

Konya City Hospital

Other

Registry information

Important dates

Study start
2026
Primary completion
2027
Study completion
2027
First posted
Jul 28, 2026
Registry last updated
Jul 28, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.